Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Apr 9:2021:6699812.
doi: 10.1155/2021/6699812. eCollection 2021.

The Clinical and Angiographic Outcomes of Postdilation after Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome: A Systematic Review and Meta-Analysis

Yan Li  1 , Xiying Liang  1 , Wenjiao Zhang  1 , Xuan Qiao  1 , Zhilu Wang  2
Affiliations
Meta-Analysis

The Clinical and Angiographic Outcomes of Postdilation after Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome: A Systematic Review and Meta-Analysis

Yan Li et al. J Interv Cardiol. .

Abstract

Objective: The effect of postdilation in patients with acute coronary syndrome is still controversial. This meta-analysis aims to analyze the clinical and angiographic outcomes of postdilation after percutaneous coronary intervention in patients with acute coronary syndrome.

Methods: PubMed, Embase, the Cochrane Library, Web of Science, CNKI, and Wangfang databases were searched from inception to August 30, 2020. Eligible studies from acute coronary syndrome patients treated with postdilation were included. The primary clinical outcome was major adverse cardiovascular events (MACE), the secondary clinical outcomes comprised all-cause death, stent thrombosis, myocardial infarction, and target vessel revascularization, and the angiographic outcomes were no reflow and slow reflow.

Results: 11 studies met inclusion criteria. In clinical outcomes, our pooled analysis demonstrated that the postdilation had a tendency of decreasing MACE (OR = 0.67, 95% CI 0.45-1.00; P = 0.05) but significantly increased all-cause death (OR = 1.49, 95% CI 1.05-2.12; P = 0.03). No significant difference existed in stent thrombosis (OR = 0.71, 95% CI 0.40-1.26; P = 0.24), myocardial infarction (OR = 1.40, 95% CI 0.51-3.83; P = 0.51), and target vessel revascularization (OR = 0.61, 95% CI 0.21-1.80; P = 0.37) between postdilation and non-postdilation groups. In angiographic outcomes, there were no significant differences in no reflow (OR = 1.19, 95% CI 0.54-2.65; P = 0.66) and slow reflow (OR = 1.12, 95% CI 0.93-1.35; P = 0.24) between two groups.

Conclusions: The postdilation tends to reduce the risk of MACE but significantly increases all-cause death, without significantly affecting stent thrombosis, myocardial infarction, target vessel revascularization, and coronary TIMI flow grade. However, more randomized controlled trials are required for investigating the effect of postdilation for patients with acute coronary syndrome (registered by PROSPERO, CRD42020160748).

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Flow chart of study selection.
Figure 2
Figure 2
Forest plot of primary clinical outcome between postdilation and non-postdilation group. Notes: MACE = major adverse cardiac events.
Figure 3
Figure 3
Forest plots of secondary clinical outcomes between postdilation and non-postdilation groups.
Figure 4
Figure 4
Forest plots of angiographic outcomes between postdilation and non-postdilation groups.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Souteyrand G., Amabile N., Mangin L., et al. Mechanisms of stent thrombosis analysed by optical coherence tomography: insights from the national PESTO French registry. European Heart Journal. 2016;37(15):1208–1216. doi: 10.1093/eurheartj/ehv711. - DOI - PubMed
    1. Fujii K., Mintz G. S., Kobayashi Y., et al. Contribution of stent underexpansion to recurrence after sirolimus-eluting stent implantation for in-stent restenosis. Circulation. 2004;109(9):1085–1088. doi: 10.1161/01.cir.0000121327.67756.19. - DOI - PubMed
    1. Brodie B. R., Cooper C., Jones M., Fitzgerald P., Cummins F. Is adjunctive balloon postdilatation necessary after coronary stent deployment? Final results from the POSTIT trial. Catheterization and Cardiovascular Interventions. 2003;59(2):184–192. doi: 10.1002/ccd.10474. - DOI - PubMed
    1. Russo R. J., Silva P. D., Teirstein P. S., et al. A randomized controlled trial of angiography versus intravascular ultrasound-directed bare-metal coronary stent placement (the AVID Trial) Circulation: Cardiovascular Interventions. 2009;2(2):113–123. doi: 10.1161/circinterventions.108.778647. - DOI - PubMed
    1. Gao Z., Yang Y.-J., Xu B., et al. Is adjunctive balloon postdilatation necessary with drug-eluting stents? One center experience in Chinese patients. Chinese Medical Journal. 2008;121(6):513–517. doi: 10.1097/00029330-200803020-00009. - DOI - PubMed

MeSH terms

LinkOut - more resources